Literature DB >> 24891271

Impact of pacing site on QRS duration and its relationship to hemodynamic response in cardiac resynchronization therapy for congestive heart failure.

Nicolas Derval1, Pierre Bordachar1, Han S Lim1, Frederic Sacher1, Sylvain Ploux1, Julien Laborderie1, Paul Steendijk2, Antoine Deplagne1, Philippe Ritter1, Stephane Garrigue1, Arnaud Denis1, Mélèze Hocini1, Michel Haissaguerre1, Jacques Clementy1, Pierre Jaïs1.   

Abstract

INTRODUCTION: Recent studies have demonstrated that left ventricular (LV) pacing site is a critical parameter in optimizing cardiac resynchronization therapy (CRT). The present study evaluates the effect of pacing from different LV locations on QRS duration (QRSd) and their relationship to acute hemodynamic response in congestive heart failure patients. METHODS AND
RESULTS: Thirty-five patients with nonischemic dilated cardiomyopathy and left bundle branch block referred for CRT device implantation were studied. Eleven predetermined LV pacing sites were systematically assessed in random order: epicardial: coronary sinus (CS); endocardial: basal and mid-cavity (septal, anterior, lateral, and inferior), apex, and the endocardial site facing the CS pacing site. For each patient QRSd and +dP/dtmax during baseline (AAI) and DDD LV pacing at 2 atrioventricular delays were compared. Response to CRT was significantly better in patients with wider baseline QRSd (≥150 milliseconds). Hemodynamic response was inversely correlated to increase of QRSd during LV pacing (short atrioventricular [AV] delay: r = 0.44, P < 0.001; long AV delay: r = 0.59, P < 0.001). Compared to baseline, LV pacing at the site of shortest QRSd significantly improved +dP/dtmax (+18 ± 25%, P < 0.001) but was not superior to other conventional strategy (lateral wall, CS pacing, and echo-guided) and was inferior to a hemodynamically guided strategy.
CONCLUSIONS: In our study, we have demonstrated that changes of QRSd during LV pacing correlated with acute hemodynamic response and that LV pacing location was a primary determinant of paced QRSd. Although QRSd did not predict the maximum hemodynamic response, our results confirm the link between electrical activation and hemodynamic response of the LV during CRT.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  acute hemodynamic; cardiac resynchronization therapy; endocardial pacing; heart failure; implantable cardioverter defibrillator; left ventricular pacing

Mesh:

Year:  2014        PMID: 24891271     DOI: 10.1111/jce.12464

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  13 in total

Review 1.  ECG Patterns In Cardiac Resynchronization Therapy.

Authors:  Antonius van Stipdonk; Sofieke Wijers; Mathias Meine; Kevin Vernooy
Journal:  J Atr Fibrillation       Date:  2015-04-30

2.  QRS prolongation after cardiac resynchronization therapy is a predictor of persistent mechanical dyssynchrony.

Authors:  Oguz Karaca; Onur Omaygenc; Beytullah Cakal; Sinem Deniz Cakal; Irfan Barutcu; Bilal Boztosun; Fethi Kilicaslan
Journal:  J Interv Card Electrophysiol       Date:  2015-12-01       Impact factor: 1.900

3.  Analysis of lead placement optimization metrics in cardiac resynchronization therapy with computational modelling.

Authors:  Andrew Crozier; Bojan Blazevic; Pablo Lamata; Gernot Plank; Matthew Ginks; Simon Duckett; Manav Sohal; Anoop Shetty; Christopher A Rinaldi; Reza Razavi; Steven A Niederer; Nicolas P Smith
Journal:  Europace       Date:  2016-12       Impact factor: 5.214

4.  Determinants of LV dP/dtmax and QRS duration with different fusion strategies in cardiac resynchronisation therapy.

Authors:  Hans Henrik Odland; Torbjørn Holm; Lars Ove Gammelsrud; Richard Cornelussen; Erik Kongsgaard
Journal:  Open Heart       Date:  2021-05

5.  Optimized Left Ventricular Endocardial Stimulation Is Superior to Optimized Epicardial Stimulation in Ischemic Patients With Poor Response to Cardiac Resynchronization Therapy: A Combined Magnetic Resonance Imaging, Electroanatomic Contact Mapping, and Hemodynamic Study to Target Endocardial Lead Placement.

Authors:  Jonathan M Behar; Tom Jackson; Eoin Hyde; Simon Claridge; Jaswinder Gill; Julian Bostock; Manav Sohal; Bradley Porter; Mark O'Neill; Reza Razavi; Steve Niederer; Christopher Aldo Rinaldi
Journal:  JACC Clin Electrophysiol       Date:  2016-12

6.  Short-Term Availability of Viable Left Ventricular Pacing Sites with Quartet™ Quadripolar Leads.

Authors:  Min Gu; Wei Hua; Xiao-Han Fan; Li-Gang Ding; Jing Wang; Hong-Xia Niu; Cong Xu; Han Jin; Shu Zhang
Journal:  Med Sci Monit       Date:  2017-02-11

Review 7.  Computational Modeling for Cardiac Resynchronization Therapy.

Authors:  Angela W C Lee; Caroline Mendonca Costa; Marina Strocchi; Christopher A Rinaldi; Steven A Niederer
Journal:  J Cardiovasc Transl Res       Date:  2018-01-11       Impact factor: 4.132

8.  A rule-based method for predicting the electrical activation of the heart with cardiac resynchronization therapy from non-invasive clinical data.

Authors:  A W C Lee; U C Nguyen; O Razeghi; J Gould; B S Sidhu; B Sieniewicz; J Behar; M Mafi-Rad; G Plank; F W Prinzen; C A Rinaldi; K Vernooy; S Niederer
Journal:  Med Image Anal       Date:  2019-07-05       Impact factor: 8.545

Review 9.  The relative role of patient physiology and device optimisation in cardiac resynchronisation therapy: A computational modelling study.

Authors:  Andrew Crozier; Bojan Blazevic; Pablo Lamata; Gernot Plank; Matthew Ginks; Simon Duckett; Manav Sohal; Anoop Shetty; Christopher A Rinaldi; Reza Razavi; Nicolas P Smith; Steven A Niederer
Journal:  J Mol Cell Cardiol       Date:  2015-11-04       Impact factor: 5.000

10.  Improvement of Right Ventricular Hemodynamics with Left Ventricular Endocardial Pacing during Cardiac Resynchronization Therapy.

Authors:  Eoin R Hyde; Jonathan M Behar; Andrew Crozier; Simon Claridge; Tom Jackson; Manav Sohal; Jaswinder S Gill; Mark D O'Neill; Reza Razavi; Steven A Niederer; Christopher A Rinaldi
Journal:  Pacing Clin Electrophysiol       Date:  2016-05-09       Impact factor: 1.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.